LJAC
AUTL

L.J. Altfest & Co’s Autolus Therapeutics AUTL Stock Holding History

L.J. Altfest & Co’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,820
Closed -$79K – 330
2024
Q3 		$79K Buy
+21,820
New +$87K 0.01% 328

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

L.J. Altfest & Co's AUTL Position: Q4 2024 in Review

L.J. Altfest & Co sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 21,820 shares — an estimated $79K sold.

L.J. Altfest & Co first reported a position in AUTL in Q3 2024 and held it in 1 quarter. The position peaked at $79K in Q3 2024. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • L.J. Altfest & Co reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • L.J. Altfest & Co sold 21,820 Autolus Therapeutics shares in Q4 2024, an estimated $79K.
  • L.J. Altfest & Co first reported a position in Autolus Therapeutics in Q3 2024 and held it in 1 quarter.
  • L.J. Altfest & Co's Autolus Therapeutics position peaked at $79K in Q3 2024.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on L.J. Altfest & Co's 13F filing for Q4 2024, filed 7 Feb 2025.